Background
==========

Nuclear factor-κB (NF-κB) belongs to a family of transcription factors that play a crucial role in inflammatory and immune reactions \[[@b2-medscimonit-21-3186]\]. The malfunctioning of NF-κB contributes to the inhibition of apoptosis, cell replication, and angiogenesis, all of which are occur in cancer cells \[[@b3-medscimonit-21-3186]\]. Several pieces of evidence have demonstrated the connection between the defective function of IκB and cancer progression. Overexpression of NF-κB has been identified in several categories of cancer, including Hodgkin's lymphoma, multiple myeloma, colorectal cancer, and melanoma \[[@b1-medscimonit-21-3186]\]. Additionally, it was discovered that the expression of IκB was decreased among prostate cancer patients \[[@b4-medscimonit-21-3186]\]. These results indicate the significant role of IκBs in regulating the oncogenic potential of NF-κB and in cancer development. From these points of view, malfunctioning in the expression of IκB may remain a risk factor for cancer.

IκBα is encoded by *NFKBIA* genes located on chromosome 14q13. *NFKBIA* rs2233406, rs3138053, and rs696 polymorphisms are situated in the binding regions for CCAAT/enhancer binding protein and GATA binding protein 2, respectively. They may regulate IκBα expression, and influence NF-κB activation; these polymorphisms (rs2233406, rs3138053, and rs696) are directly related to apoptosis, inappropriate immune cell development, and delayed cell growth \[[@b5-medscimonit-21-3186]\]. The effect of polymorphisms within the *NFKBIA* gene on cancer susceptibility has been investigated in a number of cancers \[[@b6-medscimonit-21-3186]--[@b12-medscimonit-21-3186]\]. It was reported that polymorphic variants in the 39-untranslated region of *NFKBIA* was associated with a susceptibility to multiple myeloma, Hodgkin's lymphoma, prostate cancer, breast cancer, colorectal cancer, gastric cancer, and melanoma \[[@b13-medscimonit-21-3186]--[@b19-medscimonit-21-3186]\].

However, the susceptibility modulation impacts of the polymorphisms were inconsistent in various studies because the sample sizes enrolled were limited and the ethnic backgrounds of subjects in various studies were different. Evidence of the relationship between genetic polymorphisms and cancer susceptibility can be provided by a quantitative synthesis to accumulate data from different studies. In this paper we present the results of a comprehensive meta-analysis performed on publicly available databases.

Material and Methods
====================

Literature sources and search strategy
--------------------------------------

We conducted a systematic literature search in Google Scholar, PubMed, and Web of Science databases (up to 20 June 2015) to accumulate all available studies on the association between polymorphisms of *NFKBIA* (rs2233406, rs3138053, and rs696) and cancer susceptibility by using the following the search strategy: ("*NFKBIA*" OR "Nuclear factor kappa B inhibitor") AND ("polymorphism" OR "mutation" OR "variation") AND ("susceptibility" OR "risk" OR "effects") AND ("cancer" OR "tumour" OR "carcinoma"). Studies were also searched manually on the reference lists of reviews and retrieved studies for additional eligible studies.

Inclusion and exclusion criteria
--------------------------------

The articles enrolled in the present meta-analysis were consistent with these criteria: (a) the relationship between the polymorphisms in *NFKBIA* and cancer susceptibility was identified in the studies; (b) the study method was case-control; and (c) we could extract the ORs with 95%CIs of all the cases and controls. Studies were excluded when they were: (a) studies without sufficient raw data to evaluate odds ratios with 95% confidence intervals; (b) case-only studies; (c) duplicated publications; and (d) studies based on animals or families.

Data extraction
---------------

The data were extracted independently by 3 investigators (M. Zhang, J. J. Huang, and X. X. Tan). Data with discrepancies were discussed by all authors. The following data were collected: name of first author, publication year, country of origin, ethnicity, cancer type, total numbers of cases and controls, source of controls, and genotype or allele distribution in cases and controls. Ethnic backgrounds were categorized as Asian and Caucasian.

Statistical analysis
--------------------

We assessed the relationship between the *NFKBIA* polymorphisms and cancer susceptibility by employing the ORs and 95% CIs in the studies and calculated the pooled ORs on the allele contrast (t *vs.* T), dominant (Tt+tt *vs.* TT), and recessive (tt *vs.* Tt+TT) models. Comparisons were also performed in heterozygote (Tt *vs.* TT) and homozygote (tt *vs.* TT) (TT, homozygotes for the common allele; Tt, heterozygotes; tt, homozygotes for the rare allele). The *P* values of HWE were calculated by χ^2^ test for the genotype distribution in controls. The meta-analyses were conducted by using STATA 12.0 software (Stata Corporation, College Station, Texas). A chi-square based Q-statistic test was performed to evaluate the heterogeneity of studies in the case-control studies \[[@b20-medscimonit-21-3186]\]. If the Q test (*P*\>0.1) indicated homogeneity within studies, the fixed-effects model was used \[[@b21-medscimonit-21-3186]\]; otherwise, the random-effects model was used \[[@b22-medscimonit-21-3186]\]. We also evaluated heterogeneity across studies by calculation of the inconsistency index (I^2^\<25%: no heterogeneity; I^2^=25--50%: moderate heterogeneity; I^2^\>50%: significant heterogeneity). Stratification analyses were performed by source of control, cancer type, and ethnicity. We removed a single study each time to evaluate the stability of the results. Begg's funnel plot and Egger's test were used to assess publication bias.

Results
=======

The identification and characteristics of eligible studies
----------------------------------------------------------

As demonstrated in [Figure 1](#f1-medscimonit-21-3186){ref-type="fig"}, after a systematic literature search in the databases on the relevance between *NFKBIA* polymorphisms and cancer susceptibility, a total of 107 potential records were initially identified. After checking the abstracts, 70 irrelevant studies were excluded, some studies were with insufficient data and others were duplicated studies. When the full texts were examined, we excluded 19 articles with no polymorphism studies, non-case-control studies, studies not on cancer, and reviews. Another 4 publications were excluded because they were on other polymorphisms in *NFKBIA*, were duplicates, or lacked eligible samples. Finally, 14 articles containing 28 independent case-control studies with a total of 7182 cases and 10 057 controls were enrolled in this meta-analysis \[[@b23-medscimonit-21-3186]--[@b36-medscimonit-21-3186]\]. [Table 1](#t1-medscimonit-21-3186){ref-type="table"} presents the characteristics of all eligible studies; 9 were population-based and the others were hospital-based. All studies were case-controlled, including 9 liver cancer studies, 5 colorectal cancer studies, 3 breast cancer studies, 3 prostate cancer studies, 2 oral cancer studies, 2 oesophageal cancer studies, 1 ovarian cancer study, and 1 multiple myeloma study. The ethnicities in these case-control studies were categorized as Asian (23 studies) and Caucasian (5 studies).

Pooled analysis
---------------

The primary results of the present meta-analysis and the heterogeneity test are summarized in [Table 2](#t2-medscimonit-21-3186){ref-type="table"}. In addition, we also rated the methodological quality of the included studies according to the Newcastle-Ottawa Scale ([Table 3](#t3-medscimonit-21-3186){ref-type="table"}). By pooling ORs and 95% CIs, we discovered that rs2233406 polymorphism of *NFKBIA* was not associated with susceptibility to cancers ([Table 2A](#t2A-medscimonit-21-3186){ref-type="table"}). However, we identified a significant increased susceptibility in the rs3138053 polymorphism of *NFKBIA* (C *vs.* T: OR=10.754, 95%CI=4.175--27.697, *P*~heterogeneity~=0.000; [Figure 2A](#f2A-medscimonit-21-3186){ref-type="fig"}, [Table 2B](#t2B-medscimonit-21-3186){ref-type="table"}). Another impressive finding was that the polymorphism of rs696 appeared to play a protective role in tumorigenesis, as suggested by the pooled ORs (CC+CT *vs.* TT: OR=0.879, 95%CI=0.787--0.982, *P*~heterogeneity~=0.107; [Figure 2B](#f2B-medscimonit-21-3186){ref-type="fig"}, [Table 2C](#t2C-medscimonit-21-3186){ref-type="table"}).

Subgroup analysis
-----------------

In the subgroup meta-analysis by cancer type, the rs3138053 polymorphism of *NFKBIA* was revealed to be an important factor in HCC cancer susceptibility, and the pooled results were statistically signif﻿﻿icant (C *vs.* T: OR=42.180, 95%CI=27.970--63.612, *P*~heterogeneity~=0.007; [Table 2B](#t2B-medscimonit-21-3186){ref-type="table"}). Some significantly decreased susceptibility of the rs696 polymorphism of *NFKBIA* was observed in Hodgkin lymphoma (C *vs.* T: OR=0.792, 95%CI=0.656--0.956, *P*~heterogeneity~=0.116; CC *vs.* TT: OR=0.658, 95%CI=0.448--0.965, *P*~heterogeneity~=0.076; CC *vs.* CT+TT: OR=0.734, 95%CI=0.562--0.958, *P*~heterogeneity~=0.347; [Table 2C](#t2C-medscimonit-21-3186){ref-type="table"}). The source analysis indicated positive association of the rs3138053 polymorphism in the hospital-based group (C *vs.* T: OR=10.381, 95%CI=3.513--30.677, *P*~heterogeneity~=0.000; CC+TC *vs.* TT: OR=1.405, 95%CI=1.146--1.721, *P*~heterogeneity~=0.114; CC *vs.* TC+TT: OR=2.460, 95%CI=1.686--3.590, *P*~heterogeneity~=0.867; [Table 2B](#t2B-medscimonit-21-3186){ref-type="table"}) and the population-based group (C *vs.* T: OR=11.377, 95%CI=1.472--87.963, *P*~heterogeneity~=0.000; [Table 2B](#t2B-medscimonit-21-3186){ref-type="table"}). Caucasians seems to benefit more from the polymorphism of rs696 (CT *vs.* TT: OR=0.809, 95%CI=0.676--0.969, *P*~heterogeneity~=0.459; [Table 2C](#t2C-medscimonit-21-3186){ref-type="table"}) than Asians (CT *vs.* TT: OR=0.921, 95%CI=0.691--1.227, *P*~heterogeneity~=0.015; [Table 2C](#t2C-medscimonit-21-3186){ref-type="table"}). In addition, polymorphisms that conformed to HWE in the control group showed positive association in rs2233406 (CC *vs.* CT+TT: OR=1.535, 95%CI=1.027--2.296, *P*~heterogeneity~=0.099; [Figure 2C](#f2C-medscimonit-21-3186){ref-type="fig"} and [Table 2A](#t2A-medscimonit-21-3186){ref-type="table"}) and rs3138053 (CC *vs.* TT: OR=2.133, 95%CI=1.317*--3*.455, *P*~heterogeneity~=0.217; CC *vs.* TC+TT: OR=2.063, 95%CI=1.350--3.154, *P*~heterogeneity~=0.296; [Table 2B](#t2B-medscimonit-21-3186){ref-type="table"}).

Sensitivity analysis and publication bias risk
----------------------------------------------

The sensitivity analyses were conducted by excluding each single case-control study in turn, and no separate study shows an influence on the pooled OR. Begg's funnel plot and Egger's test were performed to assess the risk of publication bias and no visual publication bias was shown (rs3138053: C *vs.* T: *P*=0.181 for egger's test; rs696: CC+CT *vs.* TT: *P*=0.552 for Egger's test, [Figure 3A](#f3A-medscimonit-21-3186){ref-type="fig"}; rs2233406: CC *vs.* CT+TT: *P*=0.175 for Egger's test, [Figure 3B](#f3B-medscimonit-21-3186){ref-type="fig"}).

Discussion
==========

The activation and translocation of NF-κB to the nucleus modulate the translation of the genes involved in inflammatory and immune activities, cell adhering, differentiating, growing, angiogenesis, and apoptosis through kinases, which leads to the phosphorylation, ubiquitination, and degradation of IκBs \[[@b37-medscimonit-21-3186]\]. The p50 subunit, encoded by the NF-κB, has several common polymorphisms in the promoter region. The promoter sequence polymorphisms contribute to an increased expression of NF-κB messenger (m) RNA. NF-κB is important to cancer pathogenesis, preventing apoptosis and enhancing growth and survival by the upregulation of several genes \[[@b38-medscimonit-21-3186]\]. Individual single-nucleotide polymorphisms (rs2233406, rs3138053, and rs696) in the *NFKBIA* gene may affect expression and function of the protein. Specifically, allelic differences in the *NFKBIA* promoter and 30UTR region may change IκBa expression and affect complex formation with NF-κB. In this way, cell growth and anti-apoptosis are regulated \[[@b39-medscimonit-21-3186]\].

Li et al. \[[@b40-medscimonit-21-3186]\] and Zou et al. \[[@b41-medscimonit-21-3186]\] reported that genetic polymorphisms of the *NFKBIA* gene were associated with cancer susceptibility and severity in sporadic colorectal cancer and oral cancer. Klein et al. \[[@b42-medscimonit-21-3186]\] proved that the polymorphism of *NFKBIA* was linked to Crohn's disease. Other studies also drew similar conclusions in breast \[[@b9-medscimonit-21-3186]\], prostate \[[@b13-medscimonit-21-3186]\], and stomach \[[@b14-medscimonit-21-3186]\] cancers. However, results from studies in various geographic areas were not consistent. To the best of our knowledge, this is the first meta-analysis to assess the relationship between these 3 polymorphisms (rs2233406, rs3138053, and rs696) of *NFKBIA* gene and overall cancer susceptibility. Our analysis validated that individuals with the variant allele (rs3138053) appear to have increased susceptibility to cancer. Interestingly, we found a contrary effect of variant allele (rs696), which seems to be associated with decreased susceptibility to cancer. In the subgroup analysis by cancer type, significantly decreased susceptibility of Hodgkin lymphoma with rs696 polymorphism was observed, whereas no significant association was found among studies of colorectal cancer.

The heterogeneity test in the present study showed that there was no evident heterogeneity in terms of the 3 polymorphisms for all cancer types between the studies. Additionally, various cancer categories did not contribute to the overall heterogeneity in association with the polymorphisms, suggesting that our present combined analyses were unbiased, regardless of cancer types. Despite the obvious advantages of our meta-analysis containing large sample sizes, some limitations of this study should be mentioned. The complex factors such as age, sex, and region may bring some bias. Studies reported in other languages may bias the present results because the negative findings are usually difficult to be included. Therefore, further study is needed to evaluate the independent and combined effect of these polymorphisms.

Conclusions
===========

In conclusion, this meta-analysis indicated that the rs3138053 polymorphism of *NFKBIA* gene is a candidate for susceptibility to overall cancers, especially in HCC cancer, while the rs696 plays a protective role against cancers, especially in Hodgkin lymphoma patients and in Caucasians. Moreover, because of the limitations described above, well-designed studies considering gene-gene and gene-environment effects should be conducted to confirm these relationships.
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###### 

Characteristics of the enrolled studies.

  SNP         First author     Year   Ethnicity   Genotyping method   Source of control   Cancer type   Control   Case                                     
  ----------- ---------------- ------ ----------- ------------------- ------------------- ------------- --------- ------ ----- ----------- --- ----- ----- -----
  rs2233406   Lu et al.        2015   Asian       PCR-RFLP            HB                  OC            478       190    19    0.982       Y   486   181   20
              Zhang et al.     2014   Asian       PCR                 HB                  HCC           1292      321    28    0.123       Y   204   41    6
              Cheng et al.     2013   Asian       PCR                 HB                  HCC           438       78     4     0.797       Y   106   27    2
              Lin et al.       2012   Asian       TaqMan              HB                  ORC           438       78     4     0.797       Y   351   101   10
              Tan et al.       2013   Asian       PCR                 HB                  CRC           163       69     5     0.459       Y   169   60    8
              Wang et al.      2014   Asian       PCR-RFLP            HB                  BC            297       162    42    **0.004**   N   212   102   32
              Wang et al.      2014   Asian       PCR-RFLP            HB                  BC            297       162    42    **0.004**   N   46    25    0
              Wang et al.      2014   Asian       PCR-RFLP            HB                  BC            297       162    42    **0.004**   N   30    20    7
              He et al.        2009   Asian       PCR                 HB                  HCC           685       181    20    0.056       Y   149   52    1
              Han et al.       2015   Asian       PCR-RFLP            HB                  PC            586       321    29    0.058       Y   508   356   72
              Umar et al.      2013   Asian       PCR                 PB                  ESCC          149       141    21    0.106       Y   145   122   23
  rs3138053   Lin et al.       2012   Asian       TaqMan              HB                  ORC           438       78     4     0.797       Y   351   101   10
              Tan et al.       2013   Asian       PCR                 HB                  CRC           163       69     5     0.459       Y   169   60    8
              Gao et al.       2014   Asian       PCR                 PB                  HCC           336       48     40    **0.000**   N   173   21    19
              Spink et al.     2006   Caucasian   PCR                 PB                  MM            94        91     11    0.066       Y   64    77    16
              He et al.        2009   Asian       PCR                 HB                  HCC           780       106    0     0.058       Y   164   38    0
              Han et al.       2015   Asian       PCR-RFLP            HB                  PC            586       321    29    0.058       Y   508   356   72
              Zhang et al.     2014   Asian       PCR                 PB                  HCC           1289      308    27    0.087       Y   214   38    1
              Cheng et al.     2013   Asian       PCR                 HB                  HCC           438       78     4     0.797       Y   106   27    2
  rs696       Umar et al.      2013   Asian       PCR                 PB                  ESCC          59        165    87    0.219       Y   71    140   79
              Gao et al.       2006   Asian       PCR-RFLP            HB                  CRC           81        259    237   0.450       Y   26    109   64
              Gao et al.       2006   Caucasian   PCR-RFLP            HB                  CRC           74        221    143   0.466       Y   29    72    54
              Zhang et al.     2014   Asian       PCR                 HB                  HCC           248       794    561   0.231       Y   55    109   84
              Gao et al.       2014   Asian       HapMap              PB                  HCC           149       196    76    0.412       Y   65    115   33
              Osborne et al.   2005   Caucasian   PCR                 PB                  HL            8         22     20    0.64        Y   4     26    21
              Chang et al.     2009   Caucasian   Taqman              PB                  HL            53        158    153   0.245       Y   92    215   156
              Han et al.       2015   Asian       PCR-RFLP            HB                  PC            165       458    313   0.909       Y   173   442   321
              Song et al.      2011   Caucasian   PCR-RFLP            PB                  CRC           212       531    262   0.06        Y   233   460   308

PCR -- polymerase chain reaction; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism; Y -- *P*~(HWE)~ \>0.05; N -- *P*~(HWE)~ ≤0.05; HCC -- hepatocellular carcinoma; OC -- ovarian cancer; BC -- breast cancer; CRC -- colorectal cancer; HL -- Hodgkin lymphoma; PC -- prostate cancer; ESCC -- esophageal squamous cell carcinoma; MM -- multiple myeloma; ORC -- oral cancer; HB -- hospital-based; PB -- population-based;

###### 

Results of meta-analysis for rs2233406 polymorphism in *NFKBA* and cancer susceptibility.

  Variables (rs2233406)   Case/control   C *vs.* T              CC *vs.* TT   CT *vs.* TT   CC+CT *vs.* TT         CC *vs.* CT+TT                                                                                                                           
  ----------------------- -------------- ---------------------- ------------- ------------- ---------------------- ---------------- ------ ---------------------- ------- ------ ---------------------- ------- ------ ---------------------------- ------- ------
  Total                   3674/7241      1.098 (0.944--1.277)   0.000         47.1          1.387 (0.942--2.042)   0.017            28.9   1.077 (0.931--1.246)   0.030   24.8   1.097 (0.937--1.283)   0.005   36.2   1.390 (0.977--1.978)         0.043   21.8
  Source of control                                                                                                                                                                                                                                         
   HB                     3384/6930      1.112 (0.942--1.312)   0.000         49.4          1.417 (0.914--2.198)   0.014            32.1   1.099 (0.941--1.284)   0.031   25.9   1.117 (0.944--1.323)   0.005   37.9   1.409 (0.940--2.111)         0.032   25.7
  Cancer type                                                                                                                                                                                                                                               
   HCC                    588/3047       1.082 (0.851--1.375)   0.236         9.5           1.038 (0.348--3.103)   0.187            16.3   1.131 (0.789--1.622)   0.082   35.8   1.115 (0.821--1.515)   0.146   23.0   1.014 (0.324--3.175)         0.165   19.9
   BC                     474/1503       0.841 (0.581--1.215)   0.132         31.2          0.390 (0.026--5.968)   0.048            55.2   1.222 (0.673--2.221)   0.693   0.0    0.889 (0.695--1.138)   0.616   0.0    0.396 (0.024--6.446)         0.043   57.0
  HWE                                                                                                                                                                                                                                                       
   Y                      3200/5738      1.148 (0.967--1.362)   0.002         48.9          1.535 (0.982--2.400)   0.046            26.1   1.103 (0.924--1.318)   0.014   36.2   1.137 (0.944--1.369)   0.004   43.7   **1.535 (1.027--2.296)\***   0.099   17.6
   N                      474/1503       0.952 (0.691--1.310)   0.096         32.9          0.994 (0.398--2.484)   0.084            35.5   0.954 (0.750--1.214)   0.624   0.0    0.949 (0.758--1.188)   0.398   0.0    1.009 (0.425--2.396)         0.094   33.3

###### 

Results of meta-analysis for rs3138053 polymorphism in *NFKBA* and cancer susceptibility.

  Variables (rs3138053)   Case/control   C *vs.* T                       CC *vs.* TT   TC *vs.* TT   CC+TC *vs.* TT               CC *vs.* TC+TT                                                                                                                                 
  ----------------------- -------------- ------------------------------- ------------- ------------- ---------------------------- ---------------- ------ ---------------------- ------- ------ ---------------------------- ------- ------ ---------------------------- ------- ------
  Total                   2595/5343      **10.754 (4.175--27.697)\***    0.000         97.8          1.683 (0.979--2.891)         0.023            34.8   1.178 (0.954--1.455)   0.012   39.9   1.209 (0.964--1.517)         0.002   48.9   1.632 (1.001--2.660)         0.055   26.3
  Source of control                                                                                                                                                                                                                                                              
   HB                     1972/3099      **10.381 (3.513--30.677)\***    0.000         97.4          2.652 (1.810--3.886)         0.767            0.0    1.335 (1.075--1.657)   0.093   24.7   **1.405 (1.146--1.721)\***   0.114   21.4   **2.460 (1.686--3.590)\***   0.867   39.0
   PB                     623/2244       **11.377 (1.472--87.963)\***    0.000         98.6          1.029 (0.415--2.551)         0.068            39.3   0.913 (0.662--1.259)   0.205   13.5   0.928 (0.639--1.347)         0.074   37.9   1.632 (1.001--2.660)         0.105   26.3
  Ethnicity                                                                                                                                                                                                                                                                      
   Asian                  2438/5147      13.628 (4.922--37.731)          0.000         97.8          1.577 (0.817--3.043)         0.013            42.9   1.168 (0.920--1.483)   0.006   44.5   1.192 (0.923_1.539)          0.001   54.9   1.553 (0.851--2.834)         0.031   35.2
  Cancer type                                                                                                                                                                                                                                                                    
   HCC                    590/3030       **42.180 (27.970--63.612)\***   0.007         63.8          0.718 (0.070--7.340)         0.077            46.2   1.206 (0.706--2.062)   0.007   63.7   1.192 (0.668--2.127)         0.003   69.1   0.716 (0.080--6.438)         0.094   41.3
  HWE                                                                                                                                                                                                                                                                            
   Y                      2382/4919      10.585 (3.663--30.581)          0.000         98.0          **2.133 (1.317--3.455)\***   0.217            8.5    1.216 (0.975--1.518)   0.012   40.1   1.260 (0.992--1.601)         0.003   49.3   **2.063 (1.350--3.154)\***   0.296   3.3
   N                      213/424        12.036 (8.430--17.184)          --            --            0.923 (0.519--1.641)         --               --     0.850 (0.493--1.465)   --      --     0.883 (0.582--1.339)         --      --     0.940 (0.530--1.667)         --      --

###### 

Results of meta-analysis for rs696 polymorphism in *NFKBA* and cancer susceptibility.

  Variables (rs696)   Case/ control   C *vs.* T                    CC *vs.* TT   CT *vs.* TT   CC+CT *vs.* TT               CC *vs.* CT+TT                                                                                                                                       
  ------------------- --------------- ---------------------------- ------------- ------------- ---------------------------- ---------------- ------ ---------------------------- ------- ------ ---------------------------- ------- ------ ---------------------------- ------- ------
  Total               3556/5705       0.952 (0.894--1.014)         0.121         13.8          0.891 (0.783--1.013)         0.194            79.5   0.884 (0.738--1.058)         0.044   24.6   **0.879 (0.787--0.982)\***   0.107   15.3   0.946 (0.811--1.103)         0.025   29.5
  Ethnicity                                                                                                                                                                                                                                                                      
   Caucasian          1670/1857       0.971 (0.882--1.069)         0.034         0.0           0.930 (0.766--1.128)         0.055            36.5   **0.809 (0.676--0.969)\***   0.459   0.0    0.851 (0.719--1.007)         0.304   3.1    1.002 (0.718--1.399)         0.010   53.7
   Asian              1886/3848       0.939 (0.863--1.021)         0.431         42.6          0.861 (0.725--1.023)         0.527            0.0    0.921 (0.691--1.227)         0.015   45.8   0.901 (0.778--1.044)         0.054   32.5   0.923 (0.798--1.068)         0.306   2.9
  Source of control                                                                                                                                                                                                                                                              
   PB                 2018/2151       0.963 (0.882--1.051)         0.047         34.2          0.906 (0.759--1.081)         0.080            27.1   0.908 (0.687--1.200)         0.050   33.4   0.887 (0.765--1.028)         0.075   28.1   0.945 (0.718--1.243)         0.016   45.0
   HB                 1538/3554       0.941 (0.858--1.031)         0.397         0.0           0.875 (0.726--1.054)         0.439            0.0    0.868 (0.656--1.148)         0.093   28.3   0.870 (0.736--1.028)         0.205   11.9   0.942 (0.781--1.136)         0.165   16.9
  Cancer type                                                                                                                                                                                                                                                                    
   HL                 514/414         **0.792 (0.656--0.956)\***   0.116         34.8          **0.658 (0.448--0.965)\***   0.076            46.6   1.126 (0.408--3.111)         0.118   34.8   0.758 (0.534--1.077)         0.080   45.3   **0.734 (0.562--0.958)\***   0.347   0.0
   CRC                1355/2020       1.003 (0.907--1.110)         0.269         5.7           1.014 (0.825--1.2480         0.702            0.0    0.901 (0.673--1.206)         0.184   16.7   0.908 (0.760--1.086)         0.726   0.0    0.995 (0.680--1.456)         0.009   62.4

I^2^ -- 0--25, means no heterogeneity; 25--50, means modest heterogeneity; \>50, means high heterogeneity; HWE -- Hardy-Weinberg equilibrium; Y -- polymorphisms conformed to HWE in the control group; N -- polymorphisms did not conform to HWE in the control group; *P*^a^ -- *P* value of Q test for heterogeneity test; \*means statistically significant (*P*\<0.05); The source of control, HB -- hospital-based; PB -- population-based; HCC -- hepatocellular carcinoma; HL -- Hodgkin lymphoma; CRC -- colorectal cancer; BC -- breast cancer.

###### 

Methodological quality of the included studies according to the Newcastle-Ottawa Scale.

              Author           Ethnicity   Adequacy of Case Definition   Representativeness of the Cases   Selection of Controls   Definition of Controls   Comparability Cases/ Controls   Ascertainment of exposure   Same method of ascertainment   Non-response rate
  ----------- ---------------- ----------- ----------------------------- --------------------------------- ----------------------- ------------------------ ------------------------------- --------------------------- ------------------------------ -------------------
  rs2233406   Lu et al.        Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Zhang et al.     Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Cheng et al.     Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Lin et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Tan et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Wang et al.      Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Wang et al.      Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Wang et al.      Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              He et al.        Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Han et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Umar et al.      Asian       \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*
  rs3138053   Lin et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Tan et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Gao et al.       Asian       \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*
              Spink et al.     Caucasian   \*                            \*                                \*                      NA                       \*\*                            \*                          \*                             \*
              He et al.        Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Han et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Zhang et al.     Asian       \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*
              Cheng et al.     Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
  rs696       Umar et al.      Asian       \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*
              Gao et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Gao et al.       Caucasian   \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Zhang et al.     Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Gao et al.       Asian       \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*
              Osborne et al.   Caucasian   \*                            \*                                \*                      NA                       \*\*                            \*                          \*                             \*
              Chang et al.     Caucasian   \*                            \*                                \*                      NA                       \*\*                            \*                          \*                             \*
              Han et al.       Asian       \*                            \*                                NA                      \*                       \*\*                            \*                          \*                             \*
              Song et al.      Caucasian   \*                            \*                                \*                      \*                       \*\*                            \*                          \*                             \*

This table identifies 'high' quality choices with a 'star'. A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. \*, Yes; NA -- not applicable. (*<http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm>*).
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